What Does Stoke Therapeutics Do?

Total employees135
HeadquartersBedford
Founded2017

Stoke Therapeutics (NASDAQ: STOK) is a clinical-stage biotechnology company dedicated to addressing the underlying cause of severe genetic diseases by developing precisely targeted medicines that restore protein expression to near-normal levels. The company is pioneering a proprietary research platform, TANGO (Targeted Augmentation of Nuclear Gene Output), to design and develop antisense oligonucleotides (ASOs) that selectively increase protein production from the healthy copy of a gene, thereby compensating for the non-functional or missing protein in genetic disorders. Stoke's initial focus is on diseases of the central nervous system and the eye, including Dravet syndrome and autosomal dominant optic atrophy (ADOA). Their lead candidate, STK-001, is in clinical development for Dravet syndrome. Stoke aims to transform the lives of patients and their families by delivering disease-modifying therapies.

Where Is Stoke Therapeutics's Headquarters?

Stoke Therapeutics officeStoke Therapeutics officeStoke Therapeutics officeStoke Therapeutics office
*Images sourced via web search. Rights belong to original owners

HQ Function

The headquarters in Bedford serves as the central hub for Stoke Therapeutics' research and development, clinical operations, and corporate functions. It houses state-of-the-art laboratories and office spaces.

Notable Features:

Modern laboratory facilities designed for advanced RNA-targeting research and oligonucleotide development. Collaborative workspaces fostering innovation among scientific and corporate teams.

Work Culture:

Stoke Therapeutics fosters a science-driven, patient-focused, and collaborative work environment. Employees are motivated by the potential to make a significant impact on the lives of individuals with severe genetic diseases. Emphasis is placed on innovation, teamwork, and scientific rigor.

HQ Significance:

Located within the Greater Boston biotech cluster, one of the world's leading hubs for life sciences innovation, providing access to talent, research institutions, and industry collaborations.

Values Reflected in HQ: The headquarters' design and functionality reflect Stoke's commitment to cutting-edge science, collaboration, and the pursuit of novel therapies for patients in need.

Location:

While headquartered in the United States, Stoke Therapeutics' clinical development programs, such as for STK-001 in Dravet syndrome, involve trial sites in multiple countries including the U.S., Canada, U.K., and Australia. This gives the company an operational reach in terms of clinical research and patient engagement across several key regions. Their strategic collaborations and partnerships may also extend internationally, supporting their mission to bring novel therapies to patients worldwide.

Street Address:

45 Wiggins Avenue

City:

Bedford

State/Province:

Massachusetts

Country:

USA

Where Else Does Stoke Therapeutics Operate Around the World?

No additional office locations available.

Buying Intent Signals for Stoke Therapeutics

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading Stoke Therapeutics? Meet the Executive Team

As of April 2025, Stoke Therapeutics' leadership includes:

Edward M. Kaye, M.D. - Chief Executive Officer
Joan W. Miller, M.D. - Chief Medical Officer
Stephen J. DiPalma - Chief Financial Officer
Gene Liau, Ph.D. - Chief Development Officer
Hu Sheng, Ph.D. - Chief Scientific Officer
Jennifer L. Allen, J.D. - Chief Legal Officer and Corporate Secretary
Heather B. Dippold, SPHR - Chief People Officer

Who's Investing in Stoke Therapeutics?

Stoke Therapeutics has been backed by several prominent investors over the years, including:

RTW Investments, LP
RA Capital Management
Perceptive Advisors
Janus Henderson Investors
BlackRock
The Vanguard Group
Apple Tree Partners

What Leadership Changes Has Stoke Therapeutics Seen Recently?

Hire1
Exits1

In the past year, Stoke Therapeutics appointed Dr. Joan W. Miller as Chief Medical Officer. This followed the transition of Dr. Barry Ticho from the CMO role to a consultant position. Other key C-suite executive positions have remained stable during this period.

Departures

Barry Ticho, M.D., Ph.D., Dr. Barry Ticho transitioned from his role as Chief Medical Officer to become a consultant for the company.

New Appointments:

Joan W. Miller, M.D., Dr. Joan W. Miller was appointed as the new Chief Medical Officer.

What Technology (Tech Stack) Is Used byStoke Therapeutics?

Discover the tools Stoke Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Stoke Therapeutics Email Formats and Examples

Stoke Therapeutics commonly utilizes an email format consisting of the employee's first initial followed by their last name. While other formats could potentially exist within the organization, this pattern is prevalent.

flast@stoketherapeutics.com

Format

ekaye@stoketherapeutics.com

Example

85%

Success rate

What's the Latest News About Stoke Therapeutics?

GlobeNewswire • May 9, 2024

Stoke Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Stoke Therapeutics reported its Q1 2024 financial results, highlighting progress in its STK-001 program for Dravet syndrome and STK-002 for ADOA. The company discussed ongoing clinical trials, patient enrollment, and upcoming data readouts....more

GlobeNewswire • March 7, 2024

Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Stoke announced its 2023 year-end financials and provided updates on its clinical programs, including advancements in STK-001 for Dravet syndrome and STK-002 for ADOA, and outlined key anticipated milestones for 2024....more

GlobeNewswire • October 2, 2023

Stoke Therapeutics Appoints Joan W. Miller, M.D., as Chief Medical Officer

Stoke Therapeutics announced the appointment of Joan W. Miller, M.D., as its new Chief Medical Officer, effective October 2, 2023. Dr. Miller brings significant experience in ophthalmology and clinical development to the company....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Stoke Therapeutics, are just a search away.